Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Another Astellas gene therapy hits a safety hurdle

How the US’s pending PIE Act will improve patient access to medication

Data backs AZ’s Wilson disease drug, but with a question mark

Fujifilm acquires AI tech to improve fertility treatment

Sarepta shares yo-yo as FDA places hold on Duchenne trial

MPO inhibitor

heart-840x470

News/ News/ R&D

AZ drug for hard-to-treat heart failure has mixed results in trial

Phil Taylor AstraZeneca, cardiovascular disease, heart failure, MPO inhibitor 0 Comment

AstraZeneca has reported the first phase 2 results with a drug for heart failure with preserved ejection fraction

X

AZ drug for hard-to-treat heart failure has mixed results in trial

https://pharmaphorum.com/news/az-drug-for-hard-to-treat-heart-failure-has-mixed-results-in-trial/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Data backs AZ's Wilson disease drug, but with a question mark
Fujifilm acquires AI tech to improve fertility treatment
Sarepta shares yo-yo as FDA places hold on Duchenne trial
Another Astellas gene therapy hits a safety hurdle

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com